The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: Results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)

Leukemia

Volumn 17, Issue 5, 2003, Pages 859-868

  Oosterveld, M ^a   Suciu, S ^b   Verhoef, G ^c   Labar, B ^d   Belhabri, A ^e   Aul, C ^f   Selleslag, D ^g   Ferrant, A ^h   Wijermans, P ⁱ   Mandelli, F ^j   Amadon, S ^k   Jehn, U ^l   Muus, P ^a   Zittoun, R ^m   Hess, U ⁿ   Anak, O ^b   Beeldens, F ^b   Willemze, R ^o   de Witte, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d KBC Zagreb   (Croatia)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g General Hospital St Jan   (Belgium)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ LEYENBURG HOSPITAL   (Netherlands)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k S EUGENIO HOSPITAL   (Italy)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^m HÔTEL DIEU   (France)

ⁿ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Donor availability; Intention to treat analysis; Myelodysplastic syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ARTICLE; AUTOGRAFT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DONOR; GENETIC RISK; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA TYPING; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIBLING; SURVIVAL RATE;

EID: 0038189644     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402897     Document Type: Article

References (32)

1. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1984; 59: 425-433.
2. Bennett JM, Catovsky D, Daniel MD, Flandrin G, Galton DAG, Gralnick HR et al. (FAB cooperative group). Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088 (erratum Blood 1998; 91: 1100).
4. O'Donnell MR, Nademanee A, Snyder DS, Schmidt GM, Parker PM, Bierman PJ et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 5: 1822-1826.
5. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukaemia. J Clin Oncol 1990; 8: 1707-1714.
6. De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990; 74: 151-155.
7. Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, Reiffers J et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 1996; 88: 358-365.
8. Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nantel SH, Klingeman HG et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplantation 1992; 10: 445-450.
9. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677-681.
10. Anderson JE, Appelbaum FR, Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leukemia Lymphoma 1995; 17: 95-99.
11. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimen and analysis of prognostic factors. Blood 1996; 87: 51-58.
12. Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A et al. On behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplantation 1998; 21: 255-260.
13. De Witte T, Muus P, De Pauw B, Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukaemia. Cancer 1990; 66: 831-837.
14. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497-501.
15. De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myelogenous leukaemia following MDS of more than 6 months duration A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment of Cancer (EORTC-LCG). Leukemia 1995; 9: 1805-1811.
16. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99: 939-944.
17. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukaemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969-2977.
18. Laporte JP, Isnard F, Lesage S, Fenaux P, Douay L, Lopez M et al. Autologous bone marrow transplantation with marrow purged by Mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia 1993; 7: 2030-2033.
19. De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia following MDS. Blood 1997; 90: 3853-3857.
20. Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet JP et al. Groupe Français des Myélodysplasies (GEM) and Groupe Ouest-Est d'étude des Leucémies aiguës myéldïdes (GOELAM). A prospective study of autologous bone marrow or peripheral stem cell transplantation in myelodysplastic syndromes. Leukemia 1999; 13: 524-529.
21. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukaemia following MDS. Blood 2001; 98: 2326-2331.
22. Mitelman F (ed): ISCN (1995). An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger.
23. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM et al. Cytogenetic pattern in acute myelogenous leukaemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403-412.
24. Kalbfleisch JD, Prentice RL. ISCN (1990). The Statistical Analysis of Failure Time Data. New York: J Wiley.
25. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578-2585.
26. Suciu S. The value of BMT in AML patients in first remission, a statistician's view-point. Ann Hematol 1991; 62: 41-44.
27. Mattijsen V, Schattenberg A, Schaap N, Preijers F, de Witte T. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplantation 1997; 19: 791-794.
28. De Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report an behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620-630.
29. Ljungman P, De Witte T, Verdonck L, Gahrton G, Freycon F, Gravett P et al. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukemia Working Party prospective analysis from HLA-typing. Br J Haematol 1993; 84: 61-66.
30. Keating S, DeWitte T, Suciu S, Willemze R, Hayat M, Labar B et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukemia Cooperative Group and GIMEMA. Br J Haematol 1998; 102: 1344-1353.
31. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplantation 1991; 7: 9-12.
32. Archimbaud E, Thomas X, Michallet M, Jauber J, Troncy J, Guyotat D et al. Prospective genetically randomized comparison between intensive postinduction chemotherapy and marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 1994; 12: 262-267.